[Points at issue in the Japanese Society of Hypertension's Guidelines for the Management of Hypertension (JSH2009)].
Ishimitsu
Toshihiko
T
D000368:Aged; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D018660:Blood Pressure Monitoring, Ambulatory; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002561:Cerebrovascular Disorders / Q000150:complications; D002648:Child; D002986:Clinical Trials as Topic; D048909:Diabetes Complications; D019317:Evidence-Based Medicine; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy*; D007564:Japan / Q000453:epidemiology; D008297:Male; D017410:Practice Guidelines as Topic; D012955:Societies, Medical
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers